Media

Media

Recent News

  • Avivagen Inc. Announces Results for Fiscal Year Ending October 31, 2020

    Ottawa, ON /Business Wire/ December 16, 2020 / — Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”) today reported its audited financial results for the fiscal year ended October 31, 2020. Unless otherwise noted, all figures are in Canadian currency. “By all measures, Avivagen achieved considerable regulatory, customer, corporate and financial success in 2020,” said …Read More

  • Avivagen Announces Expansion of Non-Dilutive Financing in Support of Increased Product Sales

    Ottawa, ON /Business Wire/ November 25, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that given the recent significant ramp up in …Read More

  • Avivagen Inc. Announces Proposed Extension of Warrants

    Ottawa, ON /Business Wire/ November 13, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”   or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune   function, thereby supporting general health and performance, announces that it will be requesting approval from …Read More

  • Avivagen Announces Non-Dilutive Financing in Support of Increased Product Sales

    Ottawa, ON /Business Wire/ October 15, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that given the recent significant ramp up in …Read More

  • Avivagen Announces Record Four Tonne Order from UNAHCO

    Four tonne order is the largest one-time purchase in Avivagen’s history, and follows UNAHCO’s three tonne order in April of this year, a previous record order Order comprised of two separate two tonne shipments that demonstrate UNAHCO’S expanded use of OxC-betaTM throughout the region. Ottawa, ON / Business Wire/ October 13, 2020 / – Avivagen …Read More

View All News Releases

Media Coverage

  • TSX At The Open

    Avivagen CEO Interviewed on C-Suite At The Open

    Kym Anthony, CEO of Avivagen, was recently interviewed by Karoline Hunter, Head of TSX Company Services at the TMX group.

    The interview covered the company story and gives a look ahead at the future of Avivagen’s OxC-BetaTM.

    The interview also covers Immune Priming, its powerful anti-inflammatory effect, and its efficacy in improving Gut Health.

View All Media Coverage